BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1047 related articles for article (PubMed ID: 31262149)

  • 21. [Organ preservation by chemoradiation for bladder cancer].
    Durdux C; Fabiano E; Méjean A
    Cancer Radiother; 2019 Oct; 23(6-7):732-736. PubMed ID: 31400955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
    Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
    Tanabe K; Yoshida S; Koga F; Inoue M; Kobayashi S; Ishioka J; Tamura T; Sugawara E; Saito K; Akashi T; Fujii Y; Kihara K
    Clin Genitourin Cancer; 2015 Aug; 13(4):e243-e251. PubMed ID: 25936588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection.
    Liang S; Zou Q; Han B; Jing Y; Cui D; An X; Gao Y; Hu J; Xia S
    Urol Int; 2015; 94(4):406-11. PubMed ID: 25678415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: Long-term results [corrected].
    Aluwini S; van Rooij PH; Kirkels WJ; Boormans JL; Kolkman-Deurloo IK; Wijnmaalen A
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):611-7. PubMed ID: 24411629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Organ-sparing treatment of bladder cancer].
    Niedworok C; Shaleva A; Rübben H; Stenzl A
    Urologe A; 2016 May; 55(5):609-14. PubMed ID: 27119956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The current status of bladder preservation in the treatment of muscle invasive bladder cancer.
    Kim HL; Steinberg GD
    J Urol; 2000 Sep; 164(3 Pt 1):627-32. PubMed ID: 10953112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bladder-sparing trimodal therapy for muscle invasive bladder cancer].
    Khalifa J; Roumiguié M; Pouessel D; Sargos P
    Cancer Radiother; 2022 Oct; 26(6-7):771-778. PubMed ID: 35970682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.
    Kozak KR; Hamidi M; Manning M; Moody JS
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e197-204. PubMed ID: 22401916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?
    Kuczyk M; Turkeri L; Hammerer P; Ravery V;
    Eur Urol; 2003 Jul; 44(1):57-64. PubMed ID: 12814676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bladder-sparing therapy for muscle-infiltrating bladder cancer.
    Pansadoro V; Emiliozzi P
    Nat Clin Pract Urol; 2008 Jul; 5(7):368-75. PubMed ID: 18560383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire.
    Chahal R; Sundaram SK; Iddenden R; Forman DF; Weston PM; Harrison SC
    Eur Urol; 2003 Mar; 43(3):246-57. PubMed ID: 12600427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.
    Kanady KE; Shipley WU; Zietman AL; Kaufman DS; Althausen AF; Heney NM
    Semin Surg Oncol; 1997; 13(5):359-64. PubMed ID: 9259092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.
    Shipley WU; Kaufman DS; Zehr E; Heney NM; Lane SC; Thakral HK; Althausen AF; Zietman AL
    Urology; 2002 Jul; 60(1):62-7; discussion 67-8. PubMed ID: 12100923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
    Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
    Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
    Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
    Leibovici D; Kassouf W; Pisters LL; Pettaway CA; Wu X; Dinney CP; Grossman HB
    Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.